Aether Industries Q3 Revenue Jumps 44%, PAT Up 49% on CEM Growth

CHEMICALS
Whalesbook Logo
AuthorRiya Kapoor|Published at:
Aether Industries Q3 Revenue Jumps 44%, PAT Up 49% on CEM Growth
Overview

Aether Industries reported a stellar Q3 FY26, with consolidated revenue surging 44% YoY to ₹3,171 Million and PAT climbing 49% YoY to ₹645 Million. The growth was propelled by increasing Contract Manufacturing (CEM) and Large Scale Manufacturing (LSM) demand, leading to a significant improvement in EBITDA margins to 34.15%. The company also added 15 new customers and is on track with capacity expansions.

📉 The Financial Deep Dive

The Numbers:
Aether Industries demonstrated exceptional financial performance in Q3 FY26, ending December 31, 2025. Consolidated operating revenue grew by a substantial 44% year-over-year (YoY) to ₹3,171 Million, alongside a 13% quarter-over-quarter (QoQ) increase. EBITDA surged by 75% YoY to ₹1,083 Million (+27% QoQ), and Profit After Tax (PAT) rose 49% YoY to ₹645 Million (+20% QoQ).

For the nine-month period (9M FY26), revenue increased 43% YoY to ₹8,534 Million, while EBITDA grew 78% YoY to ₹2,716 Million, and PAT climbed 53% YoY to ₹1,655 Million.

The Quality:
Profitability metrics saw significant improvement. EBITDA margins expanded notably to 34.15% in Q3 FY26 from 28.22% in Q3 FY25. PAT margins also saw a slight uptick from 19.75% to 20.34%. This quality enhancement is driven by operating leverage and a favourable shift towards higher-margin CEM and CRAMS business models, which now constitute over 50% of total revenue. The onboarding of 15 new customers and successful completion of 36 audits underscore operational excellence and robust customer trust.

The Grill:
While the provided text does not contain specific Q&A or contentious analyst questions, management commentary highlighted key growth drivers such as increasing CEM contracts and strong LSM demand. The focus remains on execution and leveraging operational efficiencies. There were no explicit guidance numbers or margin bands disclosed in this excerpt, but the performance metrics suggest strong execution against current market opportunities.

🚩 Risks & Outlook
The primary focus for the near-to-medium term is the successful execution of capacity expansions. Site 3++ expansion and Phase one of Site 5 expansion (two production blocks) are slated for commercial production by March 2026. R&D expansion is also on track. Potential risks, not explicitly detailed, could include execution delays in capacity expansion, global supply chain volatilities impacting raw material costs, or shifts in demand for specific chemical segments. Investors should monitor the progress of capacity commissioning and the continued ramp-up of CEM/CRAMS contracts.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.